PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT01100034
- Locations
- ππΊ
Heim Pal Children's Hospital, Budapest, Hungary
π¬π·Skin and Venereal Diseases' Hospital, Thessaloniki, Greece
π¬π·University of Athens, Andreas Syngros Hospital, Athens, Greece
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
- Conditions
- Malaria Prophylaxis
- Interventions
- Drug: test chloroquine (CQ) formulation
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01100060
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2010-08-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01099748
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain
- Conditions
- Pain
- Interventions
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 335
- Registration Number
- NCT01098747
First In Human Study Of Increasing Oral Doses Of PF-04634817
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT01098877
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: CP-601,927Other: Placebo
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 297
- Registration Number
- NCT01098240
- Locations
- πΊπΈ
Southwestern Research Incorporated, Beverly Hills, California, United States
πΊπΈSynergy Clinical Research Center, National City, California, United States
πΊπΈCollaborative Neuroscience Network, Inc., Garden Grove, California, United States
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01097876
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT01092832
- Locations
- π΅π
Medical Research Laboratory Philippine General Hospital University of the Philippines, Ermita,, Manila, Philippines
π΅πRm. 112 ICHHD, National Institutes of Health-University of the Philippines Manila, Manila, Philippines
π¨π³Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01092845
- Locations
- πΊπΈ
Pfizer Investigational Site, New York, New York, United States
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
- Conditions
- PharmacokineticPhase 1Multiple DoseSafetyToleration
- Interventions
- Drug: placebo
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01091532
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium